Annual EBITDA
-$6.52 M
-$64.50 K-1.00%
30 April 2024
Summary:
PharmaCyte Biotech annual earnings before interest, taxes, depreciation & amortization is currently -$6.52 million, with the most recent change of -$64.50 thousand (-1.00%) on 30 April 2024. During the last 3 years, it has fallen by -$2.97 million (-83.76%). PMCB annual EBITDA is now -21779.19% below its all-time high of -$29.80 thousand, reached on 30 April 2002.PMCB EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$1.27 M
-$102.70 K-8.81%
31 July 2024
Summary:
PharmaCyte Biotech quarterly earnings before interest, taxes, depreciation & amortization is currently -$1.27 million, with the most recent change of -$102.70 thousand (-8.81%) on 31 July 2024. Over the past year, it has increased by +$140.60 thousand (+9.98%). PMCB quarterly EBITDA is now -242.65% below its all-time high of $889.50 thousand, reached on 30 April 2010.PMCB Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$5.71 M
+$806.40 K+12.37%
31 July 2024
Summary:
PharmaCyte Biotech TTM earnings before interest, taxes, depreciation & amortization is currently -$5.71 million, with the most recent change of +$806.40 thousand (+12.37%) on 31 July 2024. Over the past year, it has increased by +$227.60 thousand (+3.83%). PMCB TTM EBITDA is now -857.26% below its all-time high of $754.50 thousand, reached on 31 January 2011.PMCB TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PMCB EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -1.0% | +10.0% | +3.8% |
| 3 y3 years | -83.8% | -29.5% | -53.6% |
| 5 y5 years | -60.3% | -18.9% | -42.3% |
PMCB EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -83.8% | at low | -56.4% | +45.3% | -53.6% | +18.1% |
| 5 y | 5 years | -83.8% | at low | -69.2% | +45.3% | -71.1% | +18.1% |
| alltime | all time | <-9999.0% | +65.7% | -242.7% | +84.5% | -857.3% | +69.9% |
PharmaCyte Biotech EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| July 2024 | - | -$1.27 M(+8.8%) | -$5.71 M(-12.4%) |
| Apr 2024 | -$6.52 M(+1.0%) | -$1.17 M(-37.6%) | -$6.52 M(+4.2%) |
| Jan 2024 | - | -$1.87 M(+32.6%) | -$6.26 M(+5.3%) |
| Oct 2023 | - | -$1.41 M(-32.1%) | -$5.94 M(-13.3%) |
| July 2023 | - | -$2.08 M(+129.7%) | -$6.85 M(+6.1%) |
| Apr 2023 | -$6.46 M(+52.3%) | -$903.30 K(-41.8%) | -$6.46 M(-7.4%) |
| Jan 2023 | - | -$1.55 M(-33.0%) | -$6.97 M(+11.9%) |
| Oct 2022 | - | -$2.32 M(+38.0%) | -$6.23 M(+27.4%) |
| July 2022 | - | -$1.68 M(+18.1%) | -$4.89 M(+15.5%) |
| Apr 2022 | -$4.24 M(+19.5%) | -$1.42 M(+75.4%) | -$4.24 M(+12.3%) |
| Jan 2022 | - | -$811.30 K(-17.2%) | -$3.77 M(+1.5%) |
| Oct 2021 | - | -$979.70 K(-4.4%) | -$3.72 M(+0.8%) |
| July 2021 | - | -$1.02 M(+6.9%) | -$3.69 M(+4.0%) |
| Apr 2021 | -$3.55 M(-7.3%) | -$959.00 K(+26.7%) | -$3.55 M(+6.3%) |
| Jan 2021 | - | -$756.80 K(-20.3%) | -$3.34 M(-3.4%) |
| Oct 2020 | - | -$949.50 K(+7.5%) | -$3.46 M(-3.3%) |
| July 2020 | - | -$883.60 K(+17.8%) | -$3.58 M(-6.5%) |
| Apr 2020 | -$3.83 M(-5.9%) | -$749.90 K(-14.3%) | -$3.83 M(-9.2%) |
| Jan 2020 | - | -$875.30 K(-18.0%) | -$4.22 M(+5.0%) |
| Oct 2019 | - | -$1.07 M(-5.9%) | -$4.02 M(+0.8%) |
| July 2019 | - | -$1.13 M(-0.4%) | -$3.99 M(-2.0%) |
| Apr 2019 | -$4.07 M(-41.7%) | -$1.14 M(+68.4%) | -$4.07 M(-7.1%) |
| Jan 2019 | - | -$676.30 K(-34.8%) | -$4.38 M(-23.6%) |
| Oct 2018 | - | -$1.04 M(-14.7%) | -$5.73 M(-11.9%) |
| July 2018 | - | -$1.22 M(-16.1%) | -$6.51 M(-6.8%) |
| Apr 2018 | -$6.98 M(+57.2%) | -$1.45 M(-28.7%) | -$6.98 M(+4.4%) |
| Jan 2018 | - | -$2.03 M(+11.9%) | -$6.69 M(+12.6%) |
| Oct 2017 | - | -$1.81 M(+7.5%) | -$5.94 M(+16.5%) |
| July 2017 | - | -$1.69 M(+46.2%) | -$5.10 M(+14.8%) |
| Apr 2017 | -$4.44 M(-26.9%) | -$1.15 M(-9.9%) | -$4.44 M(+0.5%) |
| Jan 2017 | - | -$1.28 M(+31.6%) | -$4.42 M(-10.3%) |
| Oct 2016 | - | -$974.20 K(-5.5%) | -$4.93 M(-11.8%) |
| July 2016 | - | -$1.03 M(-8.9%) | -$5.59 M(-8.0%) |
| Apr 2016 | -$6.07 M(-54.2%) | -$1.13 M(-36.8%) | -$6.07 M(-31.9%) |
| Jan 2016 | - | -$1.79 M(+9.5%) | -$8.92 M(+3.9%) |
| Oct 2015 | - | -$1.64 M(+8.0%) | -$8.58 M(-34.9%) |
| July 2015 | - | -$1.51 M(-61.9%) | -$13.19 M(-0.5%) |
| Apr 2015 | -$13.26 M(-30.1%) | -$3.98 M(+172.9%) | -$13.26 M(-24.2%) |
| Jan 2015 | - | -$1.46 M(-76.7%) | -$17.50 M(+6.1%) |
| Oct 2014 | - | -$6.25 M(+294.5%) | -$16.50 M(+3.7%) |
| July 2014 | - | -$1.58 M(-80.7%) | -$15.91 M(-16.2%) |
| Apr 2014 | -$18.98 M | -$8.21 M(+1705.2%) | -$18.98 M(+68.0%) |
| Jan 2014 | - | -$455.00 K(-92.0%) | -$11.30 M(+0.7%) |
| Oct 2013 | - | -$5.65 M(+21.4%) | -$11.21 M(+90.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| July 2013 | - | -$4.66 M(+777.3%) | -$5.88 M(+249.0%) |
| Apr 2013 | -$1.68 M(+3.1%) | -$530.70 K(+42.3%) | -$1.68 M(+10.9%) |
| Jan 2013 | - | -$372.90 K(+18.2%) | -$1.52 M(+10.5%) |
| Oct 2012 | - | -$315.50 K(-32.1%) | -$1.37 M(-5.5%) |
| July 2012 | - | -$464.50 K(+27.3%) | -$1.45 M(-11.0%) |
| Apr 2012 | -$1.63 M(+369.8%) | -$364.90 K(+59.6%) | -$1.63 M(+10.3%) |
| Jan 2012 | - | -$228.60 K(-42.3%) | -$1.48 M(+12.9%) |
| Oct 2011 | - | -$395.90 K(-38.5%) | -$1.31 M(+41.9%) |
| July 2011 | - | -$644.10 K(+203.0%) | -$924.40 K(+165.9%) |
| Apr 2011 | -$347.70 K(-82.6%) | -$212.60 K(+257.3%) | -$347.60 K(-146.1%) |
| Jan 2011 | - | -$59.50 K(+625.6%) | $754.50 K(-180.0%) |
| Oct 2010 | - | -$8200.00(-87.8%) | -$943.20 K(-32.0%) |
| July 2010 | - | -$67.30 K(-107.6%) | -$1.39 M(-30.5%) |
| Apr 2010 | -$1.99 M(-67.6%) | $889.50 K(-150.6%) | -$1.99 M(-72.2%) |
| Jan 2010 | - | -$1.76 M(+289.0%) | -$7.18 M(+13.8%) |
| Oct 2009 | - | -$451.70 K(-33.0%) | -$6.31 M(+0.4%) |
| July 2009 | - | -$674.60 K(-84.3%) | -$6.28 M(+3.4%) |
| Apr 2009 | -$6.15 M(+64.3%) | -$4.30 M(+386.7%) | -$6.08 M(+112.0%) |
| Jan 2009 | - | -$883.60 K(+108.2%) | -$2.87 M(-0.8%) |
| Oct 2008 | - | -$424.40 K(-9.2%) | -$2.89 M(-12.6%) |
| July 2008 | - | -$467.40 K(-57.1%) | -$3.31 M(-11.7%) |
| Apr 2008 | -$3.74 M(+3.8%) | -$1.09 M(+20.4%) | -$3.74 M(+11.2%) |
| Jan 2008 | - | -$906.10 K(+7.6%) | -$3.36 M(+4.2%) |
| Oct 2007 | - | -$842.10 K(-6.8%) | -$3.23 M(+7.0%) |
| July 2007 | - | -$904.00 K(+26.9%) | -$3.02 M(-6.2%) |
| Apr 2007 | -$3.61 M(-50.8%) | -$712.50 K(-7.4%) | -$3.22 M(-59.1%) |
| Jan 2007 | - | -$769.70 K(+22.3%) | -$7.85 M(+0.8%) |
| Oct 2006 | - | -$629.50 K(-43.0%) | -$7.79 M(+6.1%) |
| July 2006 | - | -$1.10 M(-79.4%) | -$7.35 M(+0.3%) |
| Apr 2006 | -$7.33 M(+325.8%) | -$5.35 M(+656.1%) | -$7.33 M(+108.1%) |
| Jan 2006 | - | -$707.70 K(+285.5%) | -$3.52 M(+22.8%) |
| Oct 2005 | - | -$183.60 K(-83.1%) | -$2.87 M(+3.9%) |
| July 2005 | - | -$1.08 M(-29.7%) | -$2.76 M(+37.3%) |
| Apr 2005 | -$1.72 M(-0.6%) | -$1.54 M(+2819.1%) | -$2.01 M(-5.8%) |
| Jan 2005 | - | -$52.90 K(-30.9%) | -$2.13 M(+0.8%) |
| Oct 2004 | - | -$76.60 K(-77.2%) | -$2.12 M(+3.0%) |
| July 2004 | - | -$335.60 K(-79.9%) | -$2.05 M(+18.6%) |
| Apr 2004 | -$1.73 M(+5296.0%) | -$1.67 M(+4547.9%) | -$1.73 M(+2528.4%) |
| Jan 2004 | - | -$35.90 K(+144.2%) | -$65.90 K(+56.2%) |
| Oct 2003 | - | -$14.70 K(+14.0%) | -$42.20 K(+53.5%) |
| July 2003 | - | -$12.90 K(+437.5%) | -$27.50 K(+88.4%) |
| Apr 2003 | -$32.10 K(+7.7%) | -$2400.00(-80.3%) | -$14.60 K(+19.7%) |
| Jan 2003 | - | -$12.20 K | -$12.20 K |
| Apr 2002 | -$29.80 K | - | - |
FAQ
- What is PharmaCyte Biotech annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for PharmaCyte Biotech?
- What is PharmaCyte Biotech annual EBITDA year-on-year change?
- What is PharmaCyte Biotech quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for PharmaCyte Biotech?
- What is PharmaCyte Biotech quarterly EBITDA year-on-year change?
- What is PharmaCyte Biotech TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for PharmaCyte Biotech?
- What is PharmaCyte Biotech TTM EBITDA year-on-year change?
What is PharmaCyte Biotech annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of PMCB is -$6.52 M
What is the all time high annual EBITDA for PharmaCyte Biotech?
PharmaCyte Biotech all-time high annual earnings before interest, taxes, depreciation & amortization is -$29.80 K
What is PharmaCyte Biotech annual EBITDA year-on-year change?
Over the past year, PMCB annual earnings before interest, taxes, depreciation & amortization has changed by -$64.50 K (-1.00%)
What is PharmaCyte Biotech quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of PMCB is -$1.27 M
What is the all time high quarterly EBITDA for PharmaCyte Biotech?
PharmaCyte Biotech all-time high quarterly earnings before interest, taxes, depreciation & amortization is $889.50 K
What is PharmaCyte Biotech quarterly EBITDA year-on-year change?
Over the past year, PMCB quarterly earnings before interest, taxes, depreciation & amortization has changed by +$140.60 K (+9.98%)
What is PharmaCyte Biotech TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of PMCB is -$5.71 M
What is the all time high TTM EBITDA for PharmaCyte Biotech?
PharmaCyte Biotech all-time high TTM earnings before interest, taxes, depreciation & amortization is $754.50 K
What is PharmaCyte Biotech TTM EBITDA year-on-year change?
Over the past year, PMCB TTM earnings before interest, taxes, depreciation & amortization has changed by +$227.60 K (+3.83%)